5' End Nicotinamide Adenine Dinucleotide Cap in Human Cells Promotes RNA Decay through DXO-Mediated deNADding.
5' End Nicotinamide Adenine Dinucleotide Cap in Human Cells Promotes RNA Decay through DXO-Mediated deNADding.
复制标题
DOI:
10.1016/j.cell.2017.02.019
复制
发表时间:
2017-03-09
期刊:
影响因子:
64.5
通讯作者:
Kiledjian M
中科院分区:
文献类型:
--
作者:
Jiao X;Doamekpor SK;Bird JG;Nickels BE;Tong L;Hart RP;Kiledjian M
Eukaryotic mRNAs generally possess a 5′-end m7G cap that promotes their translation and stability. However, mammalian mRNAs can also carry a 5′-end nicotinamide adenine dinucleotide (NAD+) cap that, in contrast to the m7G cap, does not support translation but instead promotes mRNA decay. The mammalian and fungal noncanonical DXO/Rai1 decapping enzymes efficiently remove NAD+ caps and cocrystal structures of DXO/Rai1 with 3′-NADP+ illuminates the molecular mechanism for how the “deNADding” reaction produces NAD+ and 5′-phosphate RNA. Removal of DXO from cells increases NAD+-capped mRNA levels and enables detection of NAD+-capped intronic snoRNAs, suggesting NAD+ caps can be added to 5′-processed termini. Our findings establish NAD+ as an alternative mammalian RNA cap and DXO as a deNADding enzyme modulating cellular levels of NAD+-capped RNAs. Collectively, these data reveal mammalian RNAs can harbor a 5′-end modification distinct from the classical m7G cap that promotes, rather than inhibits, RNA decay.